National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Hypercalcemia (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 09/29/2005



Introduction






Overview






Causes






Incidence






Symptoms







Assessment






Treatment






Get More Information From NCI






Changes to This Summary (09/29/2005)






Questions or Comments About This Summary






About PDQ



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Assessment

Laboratory assessment
Clinical assessment
Decision to treat



Laboratory assessment

A blood test is done to check the level of calcium. Other blood tests may be done to check kidney function.

Clinical assessment

Patients with high calcium levels should be examined for the following:

  • Symptoms:
    • Nerves and muscles (muscle strength, muscle tone, reflexes, tiredness, indifference, depression, confusion, restlessness).
    • Heart (high blood pressure, heart changes, irregular heartbeat, digitalis poisoning).
    • Kidneys (production of too much urine, night-time urinating, sugar in the urine, excess thirst).
    • Gastrointestinal (loss of appetite, nausea, abdominal pain, constipation, abdominal bloating).
    • Other (muscle and bone pain, itching).
  • History:
    • How fast did the symptoms appear?
    • Is there x-ray evidence of primary or metastatic bone disease?
    • Has the patient been taking tamoxifen, estrogen, or androgens?
    • Is the patient taking digoxin?
    • Is the patient receiving calcium in intravenous fluids?
    • Is the patient receiving thiazide diuretics, vitamins A or D, or lithium?
    • Is there another disease present that could cause dehydration or lack of movement?
    • Are there effective treatments for the patient's cancer?
Decision to treat

The decision to treat hypercalcemia depends on the treatment goals determined by the patient, caregivers, and the physician. The natural course of untreated hypercalcemia progresses to loss of consciousness and coma. This may be preferred by some patients at the end of life who have unrelieved suffering and/or untreatable symptoms.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov